NICE needs more evidence before recommending tirzepatide for T2DM treatment
The UK’s National Institute for Health and Care Excellence (NICE) has not recommended tirzepatide (Mounjaro, developed by Eli Lilly) in...
NICE needs more evidence before recommending tirzepatide for T2DM treatment
Journal Watch 28/06/2023
Bariatric surgery reduces mortality in patients with obesity and sleep apnoea
Despite lowering BMI threshold for eligibility, access to surgery remains low
Metabolic surgery results in fewer heart attacks, strokes and death among patients with diabetes
T2DM remains in remission six years after RYGB regardless of weight loss
Once-daily oral nonpeptide GLP-1-RA achieved up to 14.7% mean weight reduction at 36 weeks